- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03628794
Digital Supportive Care Awareness & Navigation (D-SCAN)
Pilot Testing the Digital Supportive Care Awareness & Navigation (D-SCAN) Application
Studieöversikt
Detaljerad beskrivning
D-SCAN, a digital patient navigator service in the form of a mobile application ("app"), has been designed at Duke, with feedback from Duke Cancer Institute (DCI) patients, caregivers and clinicians (screenshots in Appendix A).3 Its purpose is to facilitate awareness of available Cancer Patient Support Program (CPSP) services at Duke, and to also help patients recognize their unmet symptom management needs by answering questions from the Edmonton Symptom Assessment Scale (ESAS). This novel electronic system helps to connect patients and their loved ones with existing resources tailored to their unique situations, ensuring that no supportive care needs go unaddressed, thus improving patients' lives and their cancer care.
This protocol aims to assess the feasibility, usability, and preliminary efficacy of the D-SCAN mobile application. The app data, along with quantitative and qualitative feedback obtained during the pilot, will inform future development and design of a subsequent efficacy trial.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
North Carolina
-
Durham, North Carolina, Förenta staterna, 27705
- Duke University Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Patients who are at least age 18
- Patients who have the capacity to give consent
- Patients with advanced cancer who have initiated treatment at the DCI in the last 12 weeks
- Caregivers over the age of 18 caring for either enrolled or not enrolled patients with advanced cancer who have initiated treatment at the DCI in the last 12 weeks
Exclusion Criteria:
- Patients who are too ill to participate (per clinician discretion)
- Patients not able to read or understand English
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Stödjande vård
- Tilldelning: Randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Övrig: Intervention
Subjects in the intervention group will receive the D-SCAN mobile application
|
Subjects will receive a digital patient navigator service in the form of a mobile application ("app"), which has been designed at Duke, with feedback from Duke Cancer Institute (DCI) patients, caregivers and clinicians.
Its purpose is to facilitate awareness of available Cancer Patient Support Program (CPSP) services at Duke, and to also help patients recognize their unmet symptom management needs.
Subjects receiving the D-SCAN mobile app will also complete a survey every week within the app.
The first 15 patients and 5 caregivers randomized into the intervention arm (those receiving the app) will also be asked to participate in a qualitative interview assessment at week 12, +/- 3 weeks
|
Övrig: Control
Subjects randomized into the control group will receive standard of care which includes the routine provision of information about supportive care services by nurses and other staff in the DCI clinics, as part of the standard nurse-driven distress screening and management process
|
Subjects will receive a digital patient navigator service in the form of a mobile application ("app"), which has been designed at Duke, with feedback from Duke Cancer Institute (DCI) patients, caregivers and clinicians.
Its purpose is to facilitate awareness of available Cancer Patient Support Program (CPSP) services at Duke, and to also help patients recognize their unmet symptom management needs.
Subjects receiving the D-SCAN mobile app will also complete a survey every week within the app.
The first 15 patients and 5 caregivers randomized into the intervention arm (those receiving the app) will also be asked to participate in a qualitative interview assessment at week 12, +/- 3 weeks
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Number of enrolled patients complete at least 3 of the 12 symptom surveys over the study duration
Tidsram: 12 weeks
|
12 weeks
|
Number of patients who complete the exit survey
Tidsram: 12 weeks
|
12 weeks
|
Number of patients who return the phone
Tidsram: 12 weeks
|
12 weeks
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Frequency of use
Tidsram: 12 weeks
|
12 weeks
|
Duration of use
Tidsram: 12 weeks
|
12 weeks
|
Session Length
Tidsram: 12 weeks
|
12 weeks
|
Number of content views
Tidsram: 12 weeks
|
12 weeks
|
Number of actions taken
Tidsram: 12 weeks
|
12 weeks
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- Pro00092123
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Stödjande vård
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRekryteringCAR-T-terapikomplikationerItalien
-
Stiftung Swiss Tumor InstituteKlinik Hirslanden, Zurich; Palleos Healthcare GmbHRekryteringPatientrapporterade resultatmått | CAR T-Cell terapiSchweiz
-
The Lymphoma Academic Research OrganisationNovartis; Gilead SciencesRekryteringHematopatologi Kvalificerad eller CAR-t-cellbehandlingFrankrike
-
Henan Cancer HospitalFundamenta Therapeutics, Ltd.Har inte rekryterat ännuAllogen, CAR-T, proteinsekvestrering, icke-genredigeradKina
-
Shanghai International Medical CenterOkändAvancerad solid tumör | PD-1 antikropp | CAR-T-cellerKina
-
Ningbo Cancer HospitalOkändAvancerade maligniteter | PD-1 antikropp | CAR-T-cellerKina
-
Ruijin HospitalRekrytering
-
Shanghai General Hospital, Shanghai Jiao Tong University...RekryteringCAR-T Cell | Ph Positivt ALLA | DasatinibKina
-
Insel Gruppe AG, University Hospital BernRekryteringVaccinimmunitet hos CAR-T-cellterapimottagareSchweiz
-
Novartis PharmaceuticalsUniversity of PennsylvaniaRekryteringLångsiktig säkerhet för patienter som får CAR-T i en kvalificerad klinisk prövning eller Managed Access-programFörenta staterna, Japan, Australien, Tyskland, Spanien, Belgien, Taiwan, Italien, Kanada, Israel, Singapore, Storbritannien, Danmark, Finland, Norge, Österrike, Nederländerna, Frankrike
Kliniska prövningar på D-SCAN
-
H. Lee Moffitt Cancer Center and Research InstituteAvslutad
-
University of UtahAvslutadAlzheimers sjukdomFörenta staterna
-
Mayo ClinicAvslutadApikalt ballongsyndromFörenta staterna
-
Jonsson Comprehensive Cancer CenterAmerican Cancer Society, Inc.; LUNGevity FoundationRekryteringLungadenokarcinomFörenta staterna
-
Check-Cap Ltd.Avslutad
-
Ottawa Heart Institute Research CorporationRekryteringHjärt-kärlsjukdomarKanada
-
Centre for Addiction and Mental HealthRekryteringSchizofreni | SchizoaffektivKanada
-
Ottawa Hospital Research InstituteISBRG CorpRekrytering
-
Assiut UniversityHar inte rekryterat ännu
-
Massachusetts General HospitalNational Heart, Lung, and Blood Institute (NHLBI); Brigham and Women's...Aktiv, inte rekryterandeKardiomyopati, hypertrofiskFörenta staterna